Working… Menu

[18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04678440
Recruitment Status : Enrolling by invitation
First Posted : December 22, 2020
Last Update Posted : June 4, 2021
CellSight Technologies, Inc.
Information provided by (Responsible Party):
Simon R. Cherry, University of California, Davis

Brief Summary:
In this pilot study, healthy volunteers and patients with advanced Non-Small Cell Lung Cancer will undergo [18F]F-AraG dynamic imaging on the uEXPLORER total body Positron Emission Tomography/Computerized Tomography scanner to obtain preliminary data regarding pharmacokinetics and early biodistribution images.

Condition or disease Intervention/treatment Phase
Lung Cancer, Nonsmall Cell Drug: [18F]F-AraG Imaging Early Phase 1

Detailed Description:

[18F]F-AraG, a fluorine-18 labeled analog of an FDA approved drug (Nelarabine) is a new imaging tracer targeted at imaging activated T-cells. Given that immunotherapeutic strategies, in particular immune checkpoint antibodies, focus on the generation of T-cell-based antitumor immunity, uptake of [18F]F-AraG within the tumor is hypothesized to correlate with T-cell mediated immune response seen in the biopsy samples of cancer patients treated with immune checkpoint blockade. Correlation of pre- and post-treatment intratumoral immune infiltration by means of PET imaging will guide the development of future clinical trials investigating the role of [18F]F-AraG in the monitoring of anti-tumor immune responses. Therefore, proper quantification of [18F]F-AraG uptake in tumor lesions, and understanding its relation with physiologic uptake in background tissues is important. Note: checkpoint therapy in this study is standard-of-care and is not under investigation.

Available PET/CT scanners can obtain dynamic images only on a portion of the body as large as their axial field of view, generally anywhere between 15-30 cm. The 194 cm long uEXPLORER total-body PET scanner is the world's first device to offer the ability to tomographically image all parts of the body simultaneously. Thus, the uEXPLORER PET/CT (now commercially available and with FDA 510(k) clearance) is the only scanner in the world capable of acquiring total-body dynamic images.

In this pilot study, 2-4 healthy volunteers will undergo [18F]F-AraG dynamic imaging on the uEXPLORER total body PET/CT scanner to obtain preliminary data regarding pharmacokinetics and early biodistribution images. In addition, 2-4 patients with advanced NSCLC and planned for standard-of-care PD-1/PD-L1 immunotherapy will undergo [18F]F-AraG dynamic imaging similarly on the uEXPLORER total body PET/CT scanner to obtain data regarding pharmacokinetics of the tracer in tumor lesions in the context of normal tissue uptake. An optional second similar scan will be performed 7-14 days after the first dose of immunotherapy to explore and document any treatment related changes in [18F]F-AraG uptake and kinetics.

The study and data collected will be important to recommend an ideal time to acquire a whole body static scan using conventional and widely available PET/CT scanners for adequate tumor to background contrast and quantification, which in turn, will be essential for further clinical development of [18F]F-AraG to aid the monitoring of anti tumor immune responses.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 8 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: Healthy volunteers and patients with advanced non-small cell lung cancer will undergo identical total-body PET scans. Lung cancer patients will undergo an additional PET scans after starting treatment.
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Pilot Study of [18F]F-AraG Pharmacokinetics in Tumors and Tissue Using Dynamic Total Body PET Imaging in Healthy Subjects and in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Actual Study Start Date : March 31, 2021
Estimated Primary Completion Date : April 2022
Estimated Study Completion Date : January 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Healthy Volunteers
Study participants will undergo a single dynamic [18F]F-AraG PET/CT scan (of duration up to 90-minutes) on the uEXPLORER PET/CT scanner. There will be a follow-up visit or call 7 days after the scan to assess any adverse events that could be attributed to either the scan or the administration of [18F]F-AraG.
Drug: [18F]F-AraG Imaging
Total body PET imaging using [18F]F-AraG

Experimental: Non-Small Cell Lung Cancer Patients (NSCLC)
Study participants with NSCLC who are planned to receive PD-1/PD-L1 immunotherapy will undergo a pre-therapy dynamic [18F]F-AraG PET/CT scan, and an optional post-therapy (first dose only) dynamic [18F]F-AraG PET/CT scan on the uEXPLORER total-body scanner.
Drug: [18F]F-AraG Imaging
Total body PET imaging using [18F]F-AraG

Primary Outcome Measures :
  1. Data on whole-body pharmacokinetics of [18F]F-AraG physiologic uptake in various healthy tissues [ Time Frame: Baseline ]
    Data on [18F]F-AraG uptake in several tissue types will be collected from healthy subjects. This data will be presented in the form of time-activity curves (TAC) generated for each tissue type.

  2. Data on whole-body pharmacokinetics of [18F]F-AraG pathologic uptake in tumor lesions relative to uptake in background tissues in NSCLC subjects [ Time Frame: Baseline and 7-14 days after first dose of PD-1/PD-L1 ]
    Data on [18F]F AraG uptake in tumor lesions and background activity in the same tissues as in Outcome 1 will be collected. This data will be similarly presented in the form of time-activity curves (TAC) generated for each tissue type, as well as for tumor lesions against their background tissues.

  3. Develop recommendations for ideal time post [18F]F-AraG infusion to acquire static whole-body scans using standard PET scanners [ Time Frame: Baseline and 7-14 days after first dose of PD-1/PD-L1 ]
    Time-Activity Curves analysis of [18F]F-AraG uptake will provide insight into the earliest time to achieve adequate tumor versus non-malignant background tissue activity, as well as time to reach and remain in steady state up to 90 minutes.

Secondary Outcome Measures :
  1. Data on [18F]F-AraG uptake in advanced NSCLC before and after the first dose of PD-1/PD-L1 immunotherapy [ Time Frame: Baseline and 7-14 days after first dose of PD-1/PD-L1 ]
    For NSCLC subjects who undergo two [18F]F AraG PET/CT scans, the signal at a static time point post [18F]F-AraG infusion (obtained from the result of one of the outcome measures) from both scans will be observed for trends.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Age ≥ 18 years.
  2. Ability to understand the purposes and risks of the trial and has signed an IRB-approved informed consent form.
  3. Willingness and ability to comply with all protocol required procedures.
  4. For men and women of child-producing potential, willingness to use of effective double barrier contraceptive methods during the study, up to 1 day after the last administration of the investigational product.

    For NSCLC subjects only:

  5. Patients with histologically confirmed advanced NSCLC.
  6. Planned to undergo treatment with a PD-1 or PD-L1 inhibitor either as monotherapy or as combination therapy with concurrent chemotherapy as treatment for advanced/metastatic disease.
  7. At least 1 tumor lesion > 1 cm documented on CT or MRI or FDG-PET/CT (RECIST criteria 1.1; >1.5 cm for nodal lesions) within 45 days prior to scan date.
  8. Per investigator's assessment and in consultation with oncologists, at least one eligible lesion must be sufficiently separated from tissues with known high [18F]F-AraG uptake, such as salivary glands, bladder, liver and kidneys so that quantification will be feasible.
  9. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  10. Meeting all clinical safety lab values per institution's standard of care, or Investigator's discretion, for patients receiving cancer treatment.

Exclusion Criteria:

Subjects are not eligible if they meet ANY of the following criteria:

  1. Serious comorbidities (nonmalignant disease or other conditions) that in the opinion of the investigator could compromise protocol objectives.
  2. Pregnant women or nursing mothers.
  3. Body weight more than 240 kg (529 pounds)

    For NSCLC subjects only:

  4. Prior Treatment with anti-PD-1/PD-L1 immunotherapy.

    For Healthy subjects

  5. No primary care physician

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04678440

Layout table for location information
United States, California
UC Davis EXPLORER Molecular Imaging Center
Sacramento, California, United States, 95816
Sponsors and Collaborators
University of California, Davis
CellSight Technologies, Inc.
Layout table for investigator information
Principal Investigator: Simor R Cherry, PhD UC Davis
Layout table for additonal information
Responsible Party: Simon R. Cherry, Professor, University of California, Davis Identifier: NCT04678440    
Other Study ID Numbers: 1630355
CST-FARAG-203 ( Other Identifier: Cellsight )
First Posted: December 22, 2020    Key Record Dates
Last Update Posted: June 4, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Simon R. Cherry, University of California, Davis:
total body positron emission tomography
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms